Add to ORKGRucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma.status: publishe
Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for r...
BackgroundPoly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with hom...
Objective: An integrated analysis was undertaken to characterize the antitumor activity and safet...
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian car...
BACKGROUND: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent...
Background Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ...
Background Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ...
Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 an...
The last 2 years have ushered in a new era in ovarian cancer therapy with the US Food and Drug Admin...
The last 2 years have ushered in a new era in ovarian cancer therapy with the US Food and Drug Admin...
Recently, Poly-ADP-Ribose Polymerase (PARP) inhibitors are one of the most intensively studied group...
Abstract Background The efficacy and safety of rucaparib maintenance treatment in ARIEL3 were evalua...
BackgroundPoly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with hom...
Diana C Pearre, Krishnansu S Tewari Division of Gynecologic Oncology, Department of Obstetrics &...
Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for r...
Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for r...
BackgroundPoly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with hom...
Objective: An integrated analysis was undertaken to characterize the antitumor activity and safet...
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian car...
BACKGROUND: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent...
Background Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ...
Background Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ...
Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 an...
The last 2 years have ushered in a new era in ovarian cancer therapy with the US Food and Drug Admin...
The last 2 years have ushered in a new era in ovarian cancer therapy with the US Food and Drug Admin...
Recently, Poly-ADP-Ribose Polymerase (PARP) inhibitors are one of the most intensively studied group...
Abstract Background The efficacy and safety of rucaparib maintenance treatment in ARIEL3 were evalua...
BackgroundPoly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with hom...
Diana C Pearre, Krishnansu S Tewari Division of Gynecologic Oncology, Department of Obstetrics &...
Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for r...
Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for r...
BackgroundPoly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with hom...
Objective: An integrated analysis was undertaken to characterize the antitumor activity and safet...